Pre-Open Movers 03/12: (CEMI) (INO) (APT) Higher; (ZAGG) (NCLH) (CCL) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Inovio Pharma (INO) Misses Q4 EPS by 14c, Revenues Miss
March 12, 2020 4:30 PM EDTInovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.38), $0.14 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $279 thousand versus the consensus estimate of $2.32 million.
Dr. J. Joseph Kim, INOVIO's President & CEO, said, "The company remains well-positioned for 2020 to be a transformational year for INOVIO. Following our very encouraging, albeit... More
